All In Biotech

Drug Trial Radar · NCT03848286

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

A Phase 2 Clinical Study To Evaluate the Efficacy and Safety of KL-A167 Injection in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

153

Actual

Start

Mar 6, 2019

Primary completion

Jul 13, 2021

Study completion Jan 13, 2022

Sponsor

Sponsor type
Industry
First posted
Feb 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

Conditions

  • Nasopharyngeal Carcinoma
  • Recurrent or Metastatic

Interventions

  • KL-A167 InjectionDrug

    KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) assess by Independent Review Committee (IRC)Time frame: from first patient first visit to 12 month after last patient first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.